Friday, November 6, 2026

Tech Equities

4 articles

Semiconductor Stocks Sink 25% Even as KLA, Amkor Post Record Results

Semiconductor Stocks Sink 25% Even as KLA, Amkor Post Record Results

The SOXX semiconductor index has fallen roughly 25% from highs, with leveraged semiconductor ETFs down about 62%, even as KLA and Amkor posted record or better-than-expected quarterly results. SK hynix locked in long-term AI-memory supply deals and GlobalFoundries secured a $300M CHIPS R&D award, while Nvidia's $5B bet on Safe Superintelligence and continued M&A activity show corporate conviction in AI infrastructure has not wavered.

LM Salvado•
NVIDIA Rallies While Nobel Economist Warns AI Has Yet to Earn Its Valuation

NVIDIA Rallies While Nobel Economist Warns AI Has Yet to Earn Its Valuation

AI-exposed equities like NVIDIA continue posting outsized gains even as CPI holds at 3.8% and Nobel laureate Daron Acemoglu argues AI has delivered no measurable productivity gains. The Iran conflict has added $857 annually to average U.S. household gasoline costs, tightening consumer budgets and raising questions about whether AI investment can sustain its premium. Monetary policy uncertainty compounds the pressure on growth-stock multiples.

LM Salvado•
AI Chip Startups Pull $330M+ Rounds as Specialized Silicon Displaces General GPUs

AI Chip Startups Pull $330M+ Rounds as Specialized Silicon Displaces General GPUs

Nio GeniTech closed a $330M Series A for autonomous driving chips while photonics startup Olix plans 2027 product launch, part of a wave of custom AI silicon funding. Language Processing Units with SRAM-centric designs are emerging as alternatives to Nvidia's general-purpose GPUs. OpenAI's $840B and Anthropic's $380B valuations are accelerating enterprise demand for specialized inference chips and data center equipment.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com